Published : Jul-2019
No. of Pages : 44
1.1 List of Tables
1.2 List of Figures
2 Allergic Rhinitis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for AR (2018-2028)
3.5.1 Diagnosed Incident Cases of AR
3.5.2 Age-Specific Diagnosed Incident Cases of AR
3.5.3 Sex-Specific Diagnosed Incident Cases of AR
3.5.4 12-Month Diagnosed Prevalent Cases of AR
3.5.5 Age-Specific 12-Month Diagnosed Prevalent Cases of AR
3.5.6 Sex-Specific 12-Month Diagnosed Prevalent Cases of AR
3.5.7 12-Month Diagnosed Prevalent Cases of AR by Severity
3.5.8 12-Month Diagnosed Prevalent Cases of AR by Type of Allergen
3.5.9 12-Month Total Prevalent Cases of AR
3.5.10 Age-Specific 12-Month Total Prevalent Cases of AR
3.5.11 Sex-Specific 12-Month Total Prevalent Cases of AR
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for This Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer
List of Tables
Table 1: Risk Factors and Comorbid Conditions Associated with AR
Table 2: 7MM, 12-Month Diagnosed Prevalent Cases of AR b Type of Allergen, N, Both Sexes, Ages ?5 Years, 2018
List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of AR, N, Both Sexes, Ages ?5 Years, 2018 and 2028
Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018 and 2028
Figure 3: 7MM, 12-Month Total Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018 and 2028
Figure 4: 7MM, Diagnosed Incidence of AR (Cases per 100,000 Population), Men and Women, Ages ?5 Years, 2018
Figure 5: 7MM, 12-Month Diagnosed Prevalence of AR (%), Men and Women, Ages ?5 Years, 2018
Figure 6: 7MM, 12-Month Total Prevalence of AR (%), Men and Women, Ages ?5 Years, 2018
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of AR
Figure 8: 7MM, Sources Used to Forecast the 12-Month Diagnosed Prevalent Cases of AR
Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of AR
Figure 10: 7MM, Sources Used to Forecast the 12-Month Diagnosed Prevalent Cases of AR by Severity
Figure 11: 7MM, Diagnosed Incident Cases of AR, N, Both Sexes, ?5 Years, 2018
Figure 12: 7MM, Age-Specific Diagnosed Incident Cases of AR, N, Both Sexes, Ages ?5 Years, 2018
Figure 13: 7MM, Sex-Specific Diagnosed Incident Cases of AR, N, Ages ?5 Years, 2018
Figure 14: 7MM, 12-Month Diagnosed Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018
Figure 15: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018
Figure 16: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of AR, N, Ages ?5 Years, 2018
Figure 17: 7MM, 12-Month Diagnosed Prevalent Cases of AR by Severity, N, Both Sexes, Ages ?5 Years, 2018
Figure 18: 7MM, 12-Month Total Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018
Figure 19: 7MM, Age-Specific 12-Month Total Prevalent Cases of AR, N, Both Sexes, Ages ?5 Years, 2018
Figure 20: 7MM, Sex-Specific 12-Month Total Prevalent Cases of AR, N, Ages ?5 Years, 2018
